$1.70
3.99% day before yesterday
NYSE, Oct 24, 10:00 pm CET
ISIN
US53566P1093
Symbol
LCTX

Lineage Cell Therapeutics Stock price

$1.70
+0.10 6.25% 1M
+1.20 241.16% 6M
+1.20 238.31% YTD
+0.84 98.57% 1Y
+0.61 55.96% 3Y
+0.50 41.67% 5Y
-2.00 54.11% 10Y
+1.41 493.58% 20Y
NYSE, Closing price Fri, Oct 24 2025
+0.07 4.29%
ISIN
US53566P1093
Symbol
LCTX
Industry

Key metrics

Basic
Market capitalization
$388.2m
Enterprise Value
$346.0m
Net debt
positive
Cash
$42.3m
Shares outstanding
228.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
35.6 | 44.1
EV/Sales
31.7 | 39.3
EV/FCF
negative
P/B
8.0
Financial Health
Equity Ratio
69.2%
Return on Equity
-23.7%
ROCE
-25.5%
ROIC
-48.8%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$10.9m | $8.8m
EBITDA
$-19.8m | $-38.2m
EBIT
$-20.4m | $-40.2m
Net Income
$-40.9m | $-45.6m
Free Cash Flow
$-23.2m
Growth (TTM | estimate)
Revenue
76.3% | -7.3%
EBITDA
20.7% | -78.0%
EBIT
20.3% | -87.2%
Net Income
-69.1% | -145.0%
Free Cash Flow
-3.6%
Margin (TTM | estimate)
Gross
97.6%
EBITDA
-181.1% | -433.6%
EBIT
-186.9%
Net
-374.8% | -517.6%
Free Cash Flow
-212.1%
More
EPS
$-0.2
FCF per Share
$-0.1
Short interest
22.7%
Employees
74
Rev per Employee
$130.0k
Show more

Is Lineage Cell Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,040 stocks worldwide.

Lineage Cell Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Lineage Cell Therapeutics forecast:

11x Buy
85%
2x Hold
15%

Analyst Opinions

13 Analysts have issued a Lineage Cell Therapeutics forecast:

Buy
85%
Hold
15%

Financial data from Lineage Cell Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
11 11
76% 76%
100%
- Direct Costs 0.27 0.27
53% 53%
2%
11 11
90% 90%
98%
- Selling and Administrative Expenses 18 18
3% 3%
167%
- Research and Development Expense 13 13
5% 5%
117%
-20 -20
21% 21%
-181%
- Depreciation and Amortization 0.63 0.63
5% 5%
6%
EBIT (Operating Income) EBIT -20 -20
20% 20%
-187%
Net Profit -41 -41
69% 69%
-375%

In millions USD.

Don't miss a Thing! We will send you all news about Lineage Cell Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 70 full-time employees. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, it designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.

Head office United States
Employees 74
Website lineagecell.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today